Eisai's Leqembi subcutaneous autoinjector approved in Japan for early Alzheimer's

Eisai's Leqembi subcutaneous autoinjector has been approved in Japan for early Alzheimer's disease, allowing once-weekly 500 mg at-home self-administration, according to a press release. The approval covers a pen/autoinjector formulation for patient self-injection.

Detected & updated continuously · Source: Nebula